Vivus Is Preparing Revised TV Ads For Muse Following FDA NOV Letter
Executive Summary
Vivus is in discussions with FDA regarding revised TV broadcast ads for its erectile dysfunction therapy, Muse (alprostadil), following receipt of a notice of violation letter from the agency objecting to certain aspects of the company's TV and print ad campaigns.
You may also be interested in...
Vivus Muse Ad Omits Route Of Administration, FDA Warning Letter Says
A television advertisement for Vivus' erectile dysfunction urethral suppository Muse (alprostadil) fails to disclose the route of administration, an FDA warning letter says
Vivus Muse Ad Omits Route Of Administration, FDA Warning Letter Says
A television advertisement for Vivus' erectile dysfunction urethral suppository Muse (alprostadil) fails to disclose the route of administration, an FDA warning letter says
Journal Article Scrutiny Increases In Recent FDA Ad Division Letters
FDA is scrutinizing use of published studies in promotional campaigns more closely, recent untitled letters issued by the agency's Division of Drug Marketing, Advertising & Communication indicate.